{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:00:21Z","timestamp":1790312421649,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574452"],"award-info":[{"award-number":["82574452"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32500621"],"award-info":[{"award-number":["32500621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172644"],"award-info":[{"award-number":["82172644"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22507042"],"award-info":[{"award-number":["22507042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["226-2024-00062"],"award-info":[{"award-number":["226-2024-00062"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","award":["HHSN261201500003I"],"award-info":[{"award-number":["HHSN261201500003I"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.celrep.2026.117450","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:53:19Z","timestamp":1780005199000},"page":"117450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting EP2\/EP4-driven expansion of suppressive VSIG4high macrophages overcomes immunotherapy resistance in colorectal cancer"],"prefix":"10.1016","volume":"45","author":[{"given":"Yao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijipu","family":"Abuduaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guichao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Nussinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feixiong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Ballestar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1349-6597","authenticated-orcid":false,"given":"Weiqiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117450_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.celrep.2026.117450_bib2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib3","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117450_bib5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117450_bib6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2026.117450_bib7","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117450_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117450_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.celrep.2026.117450_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.celrep.2026.117450_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","article-title":"Therapeutic targeting of tumour myeloid cells","volume":"23","author":"Barry","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.celrep.2026.117450_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2026.117450_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","article-title":"Prostaglandin E2 in the Tumor Microenvironment, a Convoluted Affair Mediated by EP Receptors 2 and 4","volume":"76","author":"Santiso","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.celrep.2026.117450_bib15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117450_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117450_bib17","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117450_bib19","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117450_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117450_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117450_bib22","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117450_bib23","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-16-3556","article-title":"Immune-Related Gene Expression Profiling After PD-1 Blockade in Non\u2013Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma","volume":"77","author":"Prat","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117450_bib24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2021.04.036","article-title":"Tumor-Secreted Extracellular Vesicles Regulate T-Cell Costimulation and Can Be Manipulated To Induce Tumor-Specific T-Cell Responses","volume":"161","author":"Zhao","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.117450_bib25","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","article-title":"In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist","volume":"164","author":"af Forselles","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.celrep.2026.117450_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000222","article-title":"First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers","volume":"8","author":"Hong","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib27","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.chembiol.2017.12.006","article-title":"Multi-targeting Drug Community Challenge","volume":"24","author":"Schlessinger","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117450_bib28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41419-022-05434-z","article-title":"Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia","volume":"13","author":"Yi","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.celrep.2026.117450_bib29","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.celrep.2026.117450_bib30","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.23.01680","article-title":"Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB\/SWOG 80702 (Alliance)","volume":"42","author":"Nowak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.117450_bib31","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","article-title":"Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor","volume":"39","author":"Freeman-Cook","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib32","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012798","article-title":"Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer","volume":"13","author":"Lu","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.celrep.2026.117450_bib33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","article-title":"Functional states of myeloid cells in cancer","volume":"41","author":"van Vlerken-Ysla","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib34","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41467-017-01327-4","article-title":"VSIG4 inhibits proinflammatory macrophage activation by reprogramming mitochondrial pyruvate metabolism","volume":"8","author":"Li","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117450_bib35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-022-00382-6","article-title":"A novel prostaglandin E receptor 4 (EP4) small molecule antagonist induces articular cartilage regeneration","volume":"8","author":"Jin","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.celrep.2026.117450_bib36","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","article-title":"Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis","volume":"72","author":"Fong","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.celrep.2026.117450_bib37","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41590-024-02068-5","article-title":"The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer","volume":"26","author":"He","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.celrep.2026.117450_bib38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2026.117450_bib39","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.it.2020.06.010","article-title":"Organoid Models of Tumor Immunology","volume":"41","author":"Yuki","year":"2020","journal-title":"Trends Immunol."},{"key":"10.1016\/j.celrep.2026.117450_bib40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.trecan.2022.06.001","article-title":"Immune organoids: from tumor modeling to precision oncology","volume":"8","author":"Dao","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib41","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid Modeling of the Tumor Immune Microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib42","first-page":"1","article-title":"11th Edition: part I","volume":"14","year":"2017","journal-title":"Esophagus"},{"key":"10.1016\/j.celrep.2026.117450_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","article-title":"Japanese classification of gastric carcinoma: 3rd English edition","volume":"14","year":"2011","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib44","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib45","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1172\/JCI25673","article-title":"VSIG4, a B7 family-related protein, is a negative regulator of T cell activation","volume":"116","author":"Vogt","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117450_bib46","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2005.12.039","article-title":"CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens","volume":"124","author":"Helmy","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/IGC.0000000000000979","article-title":"The Significance of VSIG4 Expression in Ovarian Cancer","volume":"27","author":"Byun","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib48","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/labinvest.2014.73","article-title":"VSIG4 expression on macrophages facilitates lung cancer development","volume":"94","author":"Liao","year":"2014","journal-title":"Lab. Invest."},{"key":"10.1016\/j.celrep.2026.117450_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141115","article-title":"Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis","volume":"5","author":"Xia","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.celrep.2026.117450_bib50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.ccell.2021.05.006","article-title":"Tim-4(+) cavity-resident macrophages impair anti-tumor CD8(+) T cell immunity","volume":"39","author":"Chow","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib51","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1016\/j.devcel.2025.04.011","article-title":"Targeting VSIG4(+) tissue-resident macrophages enhances T cell cytotoxicity and immunotherapy efficacy in cancer","volume":"60","author":"Ma","year":"2025","journal-title":"Dev. Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13046-025-03303-z","article-title":"VSIG4(+) tumor-associated macrophages mediate neutrophil infiltration and impair antigen-specific immunity in aggressive cancers through epigenetic regulation of SPP1","volume":"44","author":"Pan","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2026.117450_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25116160","article-title":"Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types","volume":"25","author":"Sazinsky","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.celrep.2026.117450_bib54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Prostaglandins and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.celrep.2026.117450_bib55","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.1116221","article-title":"Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis","volume":"310","author":"Castellone","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117450_bib56","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2021.09.059","article-title":"Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer","volume":"161","author":"Wang","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.117450_bib57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Coxib and traditional NSAID Trialists' CNT Collaboration","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2026.117450_bib58","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/0008-5472.CAN-15-0125","article-title":"Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth","volume":"75","author":"Ma","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117450_bib59","doi-asserted-by":"crossref","first-page":"e15104","DOI":"10.1200\/JCO.2024.42.16_suppl.e15104","article-title":"An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors","volume":"42","author":"Xue","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.117450_bib60","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.immuni.2022.07.001","article-title":"Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment","volume":"55","author":"Gong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117450_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300606","article-title":"Design of Dual EP2\/EP4 Antagonists through Scaffold Merging of Selective Inhibitors","volume":"19","author":"Corminboeuf","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.celrep.2026.117450_bib62","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1158\/2767-9764.CRC-23-0249","article-title":"Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors","volume":"3","author":"Francica","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.celrep.2026.117450_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 Challenges in Cancer Immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117450_bib64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41586-023-05704-6","article-title":"Targeting TBK1 to overcome resistance to cancer immunotherapy","volume":"615","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117450_bib65","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117450_bib66","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.celrep.2026.117450_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.celrep.2026.117450_bib68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1053\/j.gastro.2009.12.041","article-title":"In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice","volume":"138","author":"Hunter","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.117450_bib69","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/ncb3029","article-title":"Prostaglandin signalling regulates ciliogenesis by modulating intraflagellar transport","volume":"16","author":"Jin","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.celrep.2026.117450_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100792","article-title":"Generation of an orthotopic mouse model to study colorectal cancer metastasis","volume":"2","author":"Zhang","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.celrep.2026.117450_bib71","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/j.gastro.2019.12.026","article-title":"Autophagy of Intestinal Epithelial Cells Inhibits Colorectal Carcinogenesis Induced by Colibactin-Producing Escherichia coli in Apc(Min\/+) Mice","volume":"158","author":"Lucas","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2026.117450_bib72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41589-018-0131-3","article-title":"Ligand binding to human prostaglandin E receptor EP(4) at the lipid-bilayer interface","volume":"15","author":"Toyoda","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117450_bib73","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/pro.5560030923","article-title":"Derivation of rules for comparative protein modeling from a database of protein structure alignments","volume":"3","author":"Sali","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.celrep.2026.117450_bib74","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1021\/acs.jmedchem.2c02058","article-title":"Discovery of 2H-Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy","volume":"66","author":"Cheng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117450_bib75","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1021\/acs.jmedchem.2c00448","article-title":"Scaffold Hopping Strategy to Identify Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117450_bib76","author":"Kosinski"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726005280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726005280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:31:57Z","timestamp":1790310717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726005280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":75,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2211124726005280"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117450","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting EP2\/EP4-driven expansion of suppressive VSIG4high macrophages overcomes immunotherapy resistance in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117450"}}